Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chemo-Preventative Agents Will Move To New Cancer Office In Fall

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Office of Oncology Drug Products will assume responsibility for all chemo-preventative drug reviews beginning in the fall, Office of New Drugs Director John Jenkins, MD, told reporters July 16

You may also be interested in...



FDA’s Pazdur Tapped For New Oncology Office Director

Oncology division head Pazdur is selected to lead FDA’s new Office of Oncology Drug Products following national search. Pazdur will begin assuming duties of the office May 1; the office will officially launch in July as part of a broader Office of New Drugs reorganization.

CDER Oncology Division Handling Most Cancer Prevention Drugs Ahead Of Reorg

Two approved products – Pfizer’s Celebrex and Axcan’s Photofrin – and 69 INDs were transferred to the Division of Oncology Drug Products, ahead of the creation of an Office of Oncology Drug Products. The transfer excludes biologics and those drugs aimed at reducing the risk of non-melanoma skin cancer.

CDER Oncology Division Handling Most Cancer Prevention Drugs Ahead Of Reorg

Two approved products – Pfizer’s Celebrex and Axcan’s Photofrin – and 69 INDs were transferred to the Division of Oncology Drug Products, ahead of the creation of an Office of Oncology Drug Products. The transfer excludes biologics and those drugs aimed at reducing the risk of non-melanoma skin cancer.

Related Content

Topics

UsernamePublicRestriction

Register

PS060013

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel